Gilead Sciences Inc v. Saba Ilac Sanayi Ve Ticaret As

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Gilead Sciences, Inc. (Delaware)
  • Defendant: Saba Ilac Sanayi ve Ticaret As. (Turkey)
  • Plaintiff's Counsel: Robinson Miller LLC
• Case Identification: 2:26-cv-03282, D.N.J., 03/27/2026
• Venue Allegations: Venue is asserted on the basis that Defendant is a foreign corporation subject to personal jurisdiction in the district, and thus may be sued in any judicial district.
• Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of Plaintiff's VEMLIDY® product constitutes an act of infringement of two patents related to a specific hemifumarate salt form of the active ingredient, tenofovir alafenamide.
• Technical Context: The technology concerns a specific crystalline salt form of a pharmaceutical compound used in antiviral therapies, particularly for treating Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV).
• Key Procedural History: The complaint notes Defendant has previously been sued in the District of New Jersey and has not challenged personal jurisdiction, instead filing counterclaims, which Plaintiff argues demonstrates Defendant has availed itself of the court's jurisdiction. The patents-in-suit are listed in the FDA's "Orange Book" for the VEMLIDY® product.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,754,065 - "Tenofovir Alafenamide Hemifumarate"

• Issued: June 17, 2014

The Invention Explained

• Problem Addressed: The patent background identifies tenofovir alafenamide as a prodrug of a phosphonate nucleotide analog useful in antiviral therapy '065 Patent, col. 1:17-26 While the patent also notes the existence of a monofumarate form of the compound, the invention of a new salt form addresses the ongoing need in pharmaceutical development for crystalline forms with optimal physical and chemical properties, such as stability and purity '065 Patent, col. 5:1-11
• The Patented Solution: The invention is a specific crystalline salt form of tenofovir alafenamide, known as a "hemifumarate," where the ratio of fumaric acid to tenofovir alafenamide is approximately 0.5 '065 Patent, abstract '065 Patent, col. 1:30-36 The patent asserts this hemifumarate form possesses advantages over the previously known monofumarate form, including improved thermodynamic stability, superior process reproducibility, and the ability to more easily separate the desired compound from impurities '065 Patent, col. 5:1-11 Figure 1 of the patent provides the X-ray powder diffraction (XRPD) pattern that characterizes this specific crystalline structure '065 Patent, FIG. 1
• Technical Importance: For an active pharmaceutical ingredient, creating a specific, stable, and reproducible crystalline salt form is critical for ensuring consistent quality, shelf life, and bioavailability in a final drug product.

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶35
• Claim 1:
  • Tenofovir alafenamide hemifumarate.
• The complaint does not explicitly reserve the right to assert dependent claims but references infringement of "at least one of the claims" Compl. ¶35

U.S. Patent No. 9,296,769 - "Tenofovir Alafenamide Hemifumarate"

• Issued: March 29, 2016

The Invention Explained

• Problem Addressed: As with the parent '065 Patent, this patent addresses the need for a stable and pure form of tenofovir alafenamide for pharmaceutical use '769 Patent, col. 1:20-30 The claims of this patent are directed more specifically to the purity of the final composition, addressing the technical challenge of minimizing the presence of related but undesired chemical forms, such as the monofumarate '769 Patent, col. 3:47-53
• The Patented Solution: The invention claims a pharmaceutical composition containing the tenofovir alafenamide hemifumarate salt form that is substantially pure '769 Patent, abstract The patent's solution is a composition defined by an upper limit on the amount of a specific impurity-tenofovir alafenamide monofumarate-thereby ensuring the drug product primarily consists of the desired hemifumarate form '769 Patent, claim 1 The specification highlights that the hemifumarate form has an "exceptional capability to purge" diastereomeric impurities compared to the monofumarate form '769 Patent, col. 9:36-44
• Technical Importance: Controlling impurity levels is a fundamental requirement of pharmaceutical manufacturing, as impurities can affect a drug's safety, efficacy, and stability.

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶68
• Claim 1:
  • A composition comprising tenofovir alafenamide hemifumarate,
  • wherein the composition comprises less than about 5% by weight of tenofovir alafenamide monofumarate.
• The complaint does not explicitly reserve the right to assert dependent claims but references infringement of "at least one of the claims" Compl. ¶68

III. The Accused Instrumentality

Product Identification

• Defendant's proposed generic version of VEMLIDY®, referred to as the "VEMLIDY ANDA Product" Compl. ¶7

Functionality and Market Context

• The VEMLIDY ANDA Product is a generic drug for which Defendant Saba has filed ANDA No. 220362 seeking FDA approval Compl. ¶7 Compl. ¶23 By filing an ANDA, Saba has represented to the FDA that its product has the same active ingredient, dosage form, and strength as Gilead's VEMLIDY®, and is bioequivalent Compl. ¶27 The complaint alleges the product contains tenofovir alafenamide hemifumarate Compl. ¶36 The complaint includes a figure showing the structural formula of tenofovir alafenamide fumarate, the active ingredient in VEMLIDY® Compl. ¶20
• The proposed product is intended for the same indication as VEMLIDY®: the treatment of chronic hepatitis B virus infection in adults with compensated liver disease Compl. ¶28 Compl. ¶29 The complaint alleges that upon approval, Saba intends to commercially manufacture, market, and sell its VEMLIDY ANDA Product in the United States Compl. ¶12

IV. Analysis of Infringement Allegations

U.S. Patent No. 8,754,065 Infringement Allegations

Identified Points of Contention

• Factual Question: The central question is a factual one: does the VEMLIDY ANDA Product that Saba seeks to market actually contain the specific chemical entity "tenofovir alafenamide hemifumarate" as claimed? While the complaint alleges this on information and belief, the case will depend on chemical analysis of Saba's proposed product.

U.S. Patent No. 9,296,769 Infringement Allegations

Identified Points of Contention

• Factual Question: Similar to the '065 Patent, the primary dispute will likely be factual, centering on whether Saba's proposed generic product meets the specific purity profile claimed, namely having less than 5% of the monofumarate species.
• Scope Questions: A potential point of contention may arise over the term "about 5%," which could require judicial interpretation (claim construction) to determine the precise upper boundary of the claimed purity range.

V. Key Claim Terms for Construction

'065 Patent

• The complaint does not provide sufficient detail for analysis of key claim terms.

'769 Patent

• The Term: "about 5%"
• Context and Importance: This term, found in the limitation "less than about 5% by weight," defines the purity of the claimed composition. The scope of "about" is critical because if Saba's product contains, for example, 5.1% of the monofumarate impurity, whether it infringes will depend entirely on whether "about 5%" can be interpreted to encompass that value. Practitioners may focus on this term because its construction will determine the literal boundary of the claim.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent's use of the word "about" itself suggests the patentee did not intend to be limited to a precise value of 5.00%. A party could argue that "about" should be interpreted in light of the precision of measurement techniques available in the field or the standard variability in pharmaceutical manufacturing.
  • Evidence for a Narrower Interpretation: The patent does not provide an explicit definition for "about." A party arguing for a narrower scope might contend that in the context of pharmaceutical purity, where precision is paramount, "about" should be construed narrowly to cover only minor variations or rounding, and should not be used to expand the claimed range significantly.

VI. Other Allegations

Indirect Infringement

• The complaint alleges that Saba will induce infringement by physicians and patients Compl. ¶54 Compl. ¶87 This allegation is based on the proposed label for the VEMLIDY ANDA Product, which will allegedly instruct users to administer the product to treat hepatitis B infection in a manner that directly infringes the patents Compl. ¶51 Compl. ¶84 The complaint also alleges contributory infringement, stating the product is not suitable for substantial non-infringing use Compl. ¶56 Compl. ¶89

Willful Infringement

• The complaint does not use the word "willful" but lays a foundation for such a claim. It alleges Saba has actual knowledge of the patents, at least from the date they were listed in the FDA's Orange Book, and has made efforts to market its product with full knowledge of the patents Compl. ¶¶47-49 Compl. ¶¶80-82 These allegations could be used to support a claim for enhanced damages if infringement is found.

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue will be one of factual composition: does the generic product described in Saba's ANDA contain the tenofovir alafenamide hemifumarate compound as claimed in the '065 patent, and does it meet the specific purity limitation of "less than about 5% by weight" of the monofumarate form as required by the '769 patent? The outcome will likely depend on expert chemical analysis and discovery into the composition of Saba's product.
• A secondary issue may be one of definitional scope: how should the court construe the term "about 5%"? The interpretation of this term could be dispositive if the impurity level of Saba's product is found to be near the 5% threshold, making the scope of "about" the determining factor for infringement.
• Finally, while not yet detailed, a key question will be patent validity. The case will almost certainly involve a challenge by Saba to the validity of Gilead's patents on grounds such as obviousness or lack of enablement, which are standard defenses in ANDA litigation.